ProXCath Medical, a high-tech Dutch company, specializes in delivering precision extrusions and components for the medical device and industrial sectors. Its product portfolio includes single, dual, and tri-layer extrusions, braided and coiled shafts, and balloon tubing—all meticulously engineered to meet exacting client specifications. Prioritizing speed and efficiency, ProXCath guarantees lead times of just 4–6 weeks, accelerating its clients’ time-to-market.
Beyond supplying components, the company offers end-to-end engineering and manufacturing solutions, helping clients streamline production, overcome technical challenges, and enhance yields. To further support innovation, ProXCath maintains a robust inventory of OEM components, enabling rapid prototyping and feasibility testing for new product concepts. Its unwavering commitment to quality and reliability cements its reputation as a trusted partner in the medical device manufacturing industry.
At Medical Fair India 2025, The Interview World engaged in an exclusive conversation with Miranda Huisma, Founder and CEO of ProXCath Medical. She shared deep insights into cutting-edge innovations in extrusions and components, emphasizing cost-effectiveness, product quality, and emerging market opportunities in India. She also highlighted the significance of material selection and reinforced the superior efficacy of ProXCath’s products. Here are the key takeaways from her compelling discussion.
Q: Can you share insights into ProXCath’s medical product innovations, particularly in extrusions and components? How do these advancements differentiate the company in the competitive medical device market?
A: We strive to deliver superior products that outperform others in the market. Our off-the-shelf platform sets us apart, offering clients a comprehensive, end-to-end solution. We don’t just provide finished products—we equip clients with the technology, machinery, and extrusions they need to optimize their manufacturing processes. From concept to completion, we cover everything, a capability unmatched by any other company worldwide.
Innovation drives us. We continuously integrate cutting-edge technologies to stay ahead. Our portfolio already includes cutting balloons and drug-eluting percutaneous transluminal coronary angioplasty (PTCA), and we are actively developing ultra-high-pressure balloons and other advanced solutions. Growth and progress define our approach, ensuring we always move forward.
Q: In a price-sensitive market like India, how does ProXCath balance cost-effectiveness with quality in its extrusions and components to ensure affordability for patients?
A: Our co-founder, also from India, envisioned making high-quality medical products accessible to the Indian community at fair, affordable prices. While manufacturers worldwide offer similar products, their costs remain prohibitively high. We aim to bridge this gap by delivering exceptional quality at competitive pricing. Additionally, we focus on reducing product reusability, ensuring safer and more effective medical solutions without compromising affordability.
Q: What key market opportunities do you foresee for ProXCath’s medical products in India, and how do you plan to capitalize on them?
A: No, we recently began launching our products, with the official rollout expected next month. Currently, we supply canisters to OEMs, allowing them to brand and distribute the products under their own names. Moving forward, we plan to introduce semi-compliant (SC) and non-compliant (NC) balloon catheters, with their launch anticipated next month.
Q: What materials does ProXCath use for medical products like extrusions and balloons, and how do they enhance performance and patient safety?
A: A canister comprises multiple components, each made from distinct materials. It’s not as simple as using just P-bags. Instead, a combination of various elements comes together to form a complete, functional unit. There’s no single material that defines it—it requires a carefully selected mix.
Q: How do ProXCath’s products demonstrate efficiency and reliability in critical medical emergencies, and what impact do they have on saving lives?
A: Yes, our products come into play when treating blockages. However, addressing a single blockage often requires multiple devices. We aim to streamline this process. Currently, a procedure might demand ten different canisters. With our innovations, we strive to reduce that number to six, making treatments more efficient and cost-effective.
